Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects

Psychopharmacology

Volumn 127, Issue 2, 1996, Pages 140-149

  Benjamin, Jonathan ^a   Greenberg, Benjamin D ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

ACTH; Anxiety; Blood pressure; Body temperature; Cortisol; Humans; m CPP; Mydriasis; Prolactin; Serotonin; Tolerance

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CORTICOTROPIN; HYDROCORTISONE; PLACEBO; PROLACTIN; SEROTONIN AGONIST;

ADULT; ANXIETY; ARTICLE; BEHAVIOR; BODY TEMPERATURE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG TOLERANCE; ENDOCRINE SYSTEM; FEMALE; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PUPIL; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; VOLUNTEER;

EID: 0029795360     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02805987     Document Type: Article

References (81)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders. American Psychiatric Press Washington, DC
2. 1A receptors. J Psychopharmacol 5:142-148
3. Aulakh CS, Hill JL, Murphy DL (1992a) Effects of various serotonin receptor subtype selective antagonists alone and on m-CPP-induced neuroendocrine changes in rats. J Pharmacol Exp Ther 263:588-595
4. 2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane (DOI). Psychopharmacology 109:444-448
5. Aulakh CS, Mazzola-Pomietto P, Hill JL, Murphy DL (1994a) Role of various 5-HT receptor subtypes in mediating neuroendocrine effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J Pharmacol Exp Ther 271:143-148
6. 2A receptors. J Pharmacol Exp Ther 270:127-132
7. 2C receptors, respectively. Neuropsychopharmacology 13:1-8
8. Baumann MH, Rutter JJ, Auerbach SB (1993) Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (m-CPP) increases extracellular serotonin in the diencephalon of awake rats. Neuropharmacology 32:1381-1386
9. Benjamin J, McCann U, Geraci M, Greenberg B, Murphy DL (1994) Tolerance to repeated meta-chlorophenylpipecrazine (m-CPP) challenges in panic disorder patients and healthy volunteers: a novel model for investigating possible serotonin neurotransmitter system hyperreactivity in anxiety. American College of Neuropsychopharmacology Annual Meeting Abstracts, p 163
10. Berendsen HH, Broekkamp CL (1990) Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 101:667-673
11. 1C receptors. Naunyn Schmiedeberg's Arch Pharmacol 348:221-224
12. Bonn JA, Harrison J, Rees L (1973) Lactate infusion in the treatment of "free-floating" anxiety. Can Psychiatr Assoc J 18:41-46
13. 2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (m-CPP). Eur J Pharmacol 257:27-38
14. Calogero AE, Bagdy G, Moncada ML, D'Agata R (1993) Effect of selective serotonin agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells. J Endocrinol 136:381-387
15. 3H]-5-HT from human perfused platelets. Br J Clin Pharmacol 35:473-478
16. Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of serotonin agonist m-CPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14-24
17. Coccaro EF, Siever LJ, Klar H, Rubenstein K, Benjamin E, Davis KL (1987) Diminished prolactin responses to repeated fenfluramine challenge in man. Psychiatry Res 22:257-259
18. 1C) receptors. J Pharmacol Exp Ther 242:552-557
19. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca ED (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26:311-315
20. Fong MH, Garattini S, Caccia S (1982) 1-m-Chlorophenylpiperazine is an active metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole. J Pharm Pharmacol 34:674-675
21. Freo U, Holloway HW, Greig NH, Soncrant TT (1992) Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin. Psychopharmacology 107:30-38
22. Gilmore JH, Ruegg RG, Ekstrom RD, Knight B, Carson SW, Mason GA, Golden RN (1993) Altered prolactin response to clomipramine rechallenge in healthy subjects. Biol Psychiatry 34:885-888
23. Glennon RA, Titler M, Young R (1986) Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. Psychopharmacol Bull 22:953-958
24. 2 inhalation in the treatment of panic attacks. Behav Res Ther 24:145-150
25. Hamik A, Peroutka SJ (1989) 1-(m-Chlorophenyl)piperazine (m-CPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 25:569-575
26. Hollander E, DeCaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR (1991) Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 36:1-17
27. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) International union of pharmacology classification of receptors for 5-hydrox ytryplamine (serotonin). Pharmacol Rev 46:157-203
28. Jacobsen FM, Mueller EA, Rosenthal NE, Rogers S, Hill JL, Murphy DL (1994) Behavioral responses to intravenous meta-chlorophenylpiperazine in patients with seasonal affective disorder and control subjects before and after phototherapy. Psychiatry Res 52:181-197
29. Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139-1166
30. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, van Praag HM (1990a) Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology 100: 339-344
31. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RH, van Praag HM (1990b) Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Res 33:189-198
32. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RK, van Praag HM (1991) Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects. Psychiatry Res 37:25-34
33. Kahn RS, Siever LJ, Gabriel S, Amin F, Stern RG, DuMont K, Apter S, Davidson M (1992) Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. Psychiatry Res 43:1-12
34. Kennedy AJ, Gibson EL, O'Connell MT, Curzon G (1993) Effects of housing, restraint and chronic treatments with m-CPP and sertraline on behavioural responses to m-CPP. Psychopharmacology 113:262-268
35. 1C receptors and their therapeutic relevance. Curr Opin Invest Drugs 2:317-362
36. Kennett GA, Blackburn TP (1989) Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250:809-817
37. 1C receptor antagonists. Eur J Pharmacol 164:445-454
38. 2C/2B receptor function. Neuropharmacology 12:1581-1588
39. 2C/2B receptor antagonist. Br J Pharmacol 111: 797-802
40. Kramer R, Turner P (1973) The topical and systemic effects of fenfluramine and its metabolite norfenfluramine on pupil size in healthy volunteers. J Pharm Pharmacol 25:573-576
41. Lawlor BA, Sunderland T, Hill JL, Mellow AM, Molchan SE, Mueller EA, Jacobsen KM, Murphy DL (1989a) Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects. Psychiatry Res 29:1-10
42. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL (1989b) Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. Arch Gen Psychiatry 46[6]: 542-549
43. Lawlor BA, Sunderland T, Mellow AM, Molchan SE, Martinez R, Murphy DL (1991) A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease. Biol Psychiatry 30:140-144
44. Little JT, Broocks A, Martin A, Hill JL, Mack C, Cantillon M, Molchan S, Murphy DL, Sunderland T (1996) Serotonergic modulation of anticholinergic effects in cognition and behavior in elderly humans. Psychopharmacology (in press)
45. Maj J, Moryl E (1992) Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm 88:143-156
46. Mazzola-Pomietto P, Aulakh CS, Murphy DL (1994a) Evidence that seperate mechanisms mediate m-CPP and DOI-induced ACTH secretion in the rat. J Pharmacol Exp Ther (in press)
47. 2C receptors. Psychopharmacology 123:333-339
48. Mellow AM, Lawlor BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL (1990) Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients: initial experience with a serotonin agonist. Biol Psychiatry 28:588-594
49. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43:320-327
50. Mueller EA, Murphy DL, Sunderland T (1985) Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol 61:1179-1184
51. Mueller EA, Murphy DL, Sunderland T (1986) Further studies of the putative serotonin agonist m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology 89:388-391
52. Murphy DL, Mueller FA, Hill JL, Tolliver TJ, Jacobsen FM (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology 98:275-282
53. Murphy DL, Lesch KP, Aulakh CS, Pigott TA (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 43:527-552
54. Murphy DL, Aulakh CS, Mazzola-Pomietto P, Briggs NC (1996) Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: a preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures. Behav Brain Res 73:209-214
55. Owen RRJ, Gutierrez-Esteinou R, Hsiao J, Hadd K, Benkelfat C, Lawlor BA, Murphy DL, Pickar D (1993) Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 50:636-644
56. Pigott TA, Zohar J, Hill JL, Bernstein SF, Grover GN, Zohar-Kadouch RC, Murphy DL (1991) Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry 29:418-426
57. Pigott TA, L'Heureux F, Bernstein SH, Hill JL, Murphy DL (1992) A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazine (m-CPP) in patients with obsessive-compulsive disorder. NCDEU Annual Meeting Abstracts. May 26-29
58. Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL (1993) A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patients and the effect of metergoline prior to IV m-CPP. Biol Psychiatry 33:3-14
59. 1C/2 receptor agonists and antagonists. Eur J Pharmacol [Mol Pharmacol Sec] 244:1-5
60. Pratt J (1991) The biological bases of drug tolerance and dependence. Academic Press, San Diego
61. Pyke RE, Greenberg HS (1986) Norepinephrine challenges in panic patients. J Clin Psychopharmocol 6:279-285
62. 1A (antagonistic) activity. Psychopharmacology 108:320-326
63. 2 receptors. Life Sci 50:599-605
64. 1C receptor reserve in choroid plexus masks receptor subsensitivity. J Pharmacol Exp Ther 252:984-988
65. 2 antagonists in rats. Psychopharmacology 94:342-346
66. 1B receptor ligands exist? Naunyn-Schmiedeberg's Arch Pharmacol 339:675-683
67. Schwartz PJ, Wehr TA, Rosenthal NE, Bartko JJ, Oren DA, Luetke C, Murphy DL (1995) Serotonin and thermoregulation: physiologie and pharmacologic aspects of control revealed by intravenous m-CPP in normal human subjects. Neuropsychopharmacology 13:105-115
68. Scibyl JP, Krystal JH, Price LH, Woods SW, D'Amico C, Heninger GR, Charnry DS (1991) Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 38:227-236
69. Sills MA, Lucki I, Frazer A (1985) Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or m-CPP. Life Sci 36:2463-2469
70. 7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Mol Pharmacol 47:99-103
71. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R (SCID, version 1.0). American Psychiatric Press, Washington, DC
72. Stewart J, Badiani A (1993) Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 4:289-312
73. Stoff DM, Pasatiempo AP, Yeung JH, Bridger WH, Rabinovich H (1992) Test-retest reliability of the prolactin and cortisol responses to D,L.-fenfluramine challenge in disruptive behavior disorders. Psychiatry Res 42:65-72
74. 2C serotonin receptors. Nature 374: 542-546
75. Ulrichsen J, Partilla JS, Dax EM (1992) Long-term administration of m-chlorophenylpiperazine (m-CPP) to rats induces changes in serotonin receptor binding, dopamine levels and locomotor activity without altering prolactin and corticosterone secretion. Psychopharmacology 107:229-235
76. Walsh AE, Cowen PJ (1994) Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 14:268-273
77. Walsh SL, Preston KL, Sullivan JT, Fromme R, Bigelow GE (1994) Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14:396-407
78. Wolf WA, Kuhn DM (1991) The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP. Neurochem Int 19:39-44
79. Young AM, Goudie AJ (1995) Adaptive processes regulating tolerance to behavioral effects of drugs. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Chapter 64. Raven Press, New York, pp 733-742
80. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987) Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry 44:946-951
81. Zohar J, Insel TR, Zohar-Kadouch RC, Hill JL, Murphy DL (1988) Serotonergic responsivity in obsessive-compulsive disorder: effects of chronic clomipramine treatment. Arch Gen Psychiatry 45:167-172